Literature DB >> 8845091

Hypertension in patients with diabetes mellitus.

J S Skyler1, J B Marks, N Schneiderman.   

Abstract

Diabetes mellitus and hypertension each confer increased cardiovascular risk. That risk is much greater when the diseases coexist and is further magnified by their frequent association with dyslipidemia and central obesity. Insulin resistance appears to be an important common component to these four entities, whether or not the relationship is truly cause and effect. Increased renal tubule absorption of sodium and increased sympathetic nervous system stimulation from insulin have been said to be the mechanisms by which elevated levels of insulin cause hypertension. However, animal experiments suggest that these are short-term effects only and that long-term insulin may actually increase peripheral blood flow and reduce blood pressure. Experiments in humans suggest that the insulin resistant state in obese patients and type II diabetics is associated with a decrease of the usual vasodilatory effect of insulin. Antihypertensive drugs have differing effects on insulin resistance. Angiotensin converting enzyme inhibitors, alpha-adrenergic blockers, and dihydropyridines appear to improve insulin sensitivity. Other calcium channel blockers appear to be neutral, as is furosemide. Thiazide diuretics, spironolactone, and beta-adrenergic blockers impair insulin sensitivity. The drugs that increase insulin sensitivity also tend to improve dyslipidemia or remain lipid neutral. In contrast, those drugs that tend to impair insulin sensitivity also tend to worsen dyslipidemia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8845091     DOI: 10.1016/0895-7061(95)00307-x

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  6 in total

1.  Clinical problem solving based on the 1999 Canadian recommendations for the management of hypertension.

Authors:  R D Feldman; N R Campbell; P Larochelle
Journal:  CMAJ       Date:  1999       Impact factor: 8.262

2.  1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension.

Authors:  R D Feldman; N Campbell; P Larochelle; P Bolli; E D Burgess; S G Carruthers; J S Floras; R B Haynes; G Honos; F H Leenen; L A Leiter; A G Logan; M G Myers; J D Spence; K B Zarnke
Journal:  CMAJ       Date:  1999       Impact factor: 8.262

Review 3.  Perturbed autonomic nervous system function in metabolic syndrome.

Authors:  Nicholas Tentolouris; Georgia Argyrakopoulou; Nicholas Katsilambros
Journal:  Neuromolecular Med       Date:  2008-01-26       Impact factor: 3.843

Review 4.  Does the sympathetic nervous system contribute to the pathophysiology of metabolic syndrome?

Authors:  Marina C Dos Santos Moreira; Izabella S de Jesus Pinto; Aline A Mourão; James O Fajemiroye; Eduardo Colombari; Ângela A da Silva Reis; André H Freiria-Oliveira; Marcos L Ferreira-Neto; Gustavo R Pedrino
Journal:  Front Physiol       Date:  2015-08-25       Impact factor: 4.566

Review 5.  Molecular mechanisms linking stress and insulin resistance.

Authors:  Habib Yaribeygi; Mina Maleki; Alexandra E Butler; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  EXCLI J       Date:  2022-01-24       Impact factor: 4.068

6.  Isolated systolic hypertension and its associated risk factors in Iranian middle age and older population: a population-based study.

Authors:  Ali Hosseinzadeh; Hossein Ebrahimi; Ahmad Khosravi; Mohammad Hassan Emamian; Hassan Hashemi; Akbar Fotouhi
Journal:  BMC Cardiovasc Disord       Date:  2022-09-27       Impact factor: 2.174

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.